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Summary and Implications 
 Porcine Reproductive and Respiratory Syndrome 
(PRRS) imposes a huge financial burden on the swine 
industry. Thus, there is a clear and immediate need for 
improved PRRS virus (PRRSV) vaccines.  Our group has 
proposed a new classification scheme for PRRSV strains 
that allows for immunological differentiation based on level 
of GP5 glycosylation. This classification based on 
glycantype has allowed us to choose PRRSV strains that 
offer the best chance of protection against PRRS. 
 
Introduction 
 The protective role of antibodies against PRRSV has 
been demonstrated by Osorio et al., who used hyperimmune 
serum to protect pregnant sows and their piglets from 
PRRSV infection. The importance of the GP5-M 
heterodimer for PRRSV has been demonstrated, as has 
equivalent protein heterodimers in other Arteriviruses. 
There are published studies which indicate that co-
expression of both GP5 and M of PRRSV result in enhanced 
humoral and cell-mediated immune responses, and could 
therefore be effective at preventing PRRS. Similar studies 
with Equine Arteritis Virus (EAV) have also shown that the 
envelope proteins GL and M, the equivalent of PRRSV GP5 
and M respectively, do induce an antibody response, but 
only antibodies to the heterodimer were able to neutralize 
EAV and provided greater protection in vivo. These results 
indicate the necessity of the GP5-M heterodimer to induce a 
protective antibody response to protect against PRRSV. 
 
Materials and Methods 
 Eight PRRSV negative gilts were inoculated with 
PRRSV strain HLV013 on Day 0 at 62 days of age, boosted 
with HLV013 on Day 52, and necropsied for serum 
collection on Day 86. Serum was then tested by fluorescent 
focus neutralization (FFN) on MARC-145 cells to determine 
virus neutralization titers. A second similar study was also 
done following the same infection schedule, except on Day 
52 the eight gilts were boosted with PRRSV strain HLV093.   
 Preparation of GP5-M heterodimer glycantype specific 
recombinant protein and replicon particles 
PRRSV strains HLV013 and HLV093 served as the parent 
strains for recombination.  The PRRSV GP5 and M genes 
from each strain were cloned into replicon vectors that are 
based on a live attenuated strain of Venezuelan Equine 
Encephalitis Virus (VEEV). The GP5 and M replicon 
vectors were analyzed by both IFA and Western blot to 
confirm expression desired proteins.  These replicons were 
then packaged into particles via co-electroporation with 
helper VEEV RNAs to produce RP. These same replicons 
were also co-electroporated without helper VEEV RNAs to 
produce recombinant protein. 
 
Results and Discussion 
 PRRSV strains with two N-linked glycans in the GP5 
ectodomain, regardless of amino acid position, were 
designated NA2 strains. Strains with three N-linked glycans 
were designated NA3, and strains with 4 N-linked glycans 
were designated NA4. Although not used in this study, the 
glycantype scheme can easily be used for strains with 
additional glycans. Glycantype results are given in Table 1. 
Our data indicate that glycantype is the best predictor of 
cross neutralization when compared to ORF5 homology and 
RFLP patterns. As the number of N-linked glycans on GP5 
increases so does resistance to neutralization by high titer 
sera. Several studies have shown that PRRSV strains with 
fewer glycans located in the GP5 ectodomain can induce 
neutralizing titers more rapidly and to a higher level than 
wild-type strains. The same results were seen in this study. 
When only one NA2 strain, HLV013, was used to infect the 
gilts, the highest homologous FFN titer observed was 140.4. 
However, when an additional NA2 strain, HLV093, was 
used to boost after HLV013 infection, there was a 
significant increase in FFN titers. High virus neutralizing 
titers were induced against all glycantypes when two NA2 
strains were used. All titers seen after infection with two 
different NA2 strains are considered protective based on 
previous work. However, there are no current commercially 
available vaccines that fall into the NA2 group. This data 
supports the hypothesis that a vaccine which incorporates 
glycan mutant NA2 strains could be protective against 
PRRSV. 
 Recombinant proteins and replicon particles have been 
prepared with GP5 and M genes from 3 strains of PRRSV: 
HLV013 (NA2), HLV093 (NA2), and HLV349 (NA4). 
These preparations are being evaluated experimentally as 
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Table 1. Glycantype results.  Strains are ordered highest to lowest by mean FFN results. 
 
Mean FFN titer for each treatment group PRRSV Strain 




HLV013, HLV013 HLV013, HLV093 
HLV013 NA2 (44,51) 100 1-4-2 140.4 1216 
ISU-P NA2 (44,51) 90 1-5-2 91.2 861 
NVSL 97-7895 NA3 (24,44,51) 99 1-4-2 54.3 363 
SDSU 23983 NA3 (34,44,51) 89 1-6-2 15.9 65 
Prime Pac NA3 (30,44,51) 89 1-4-4 14.7 513 
VR2332 NA4 (30,33,44,51) 90 2-5-2 4.7 129 
HLV375 NA4 (32,33,44,51) 87 1-18-2 4.0 64 
MN184b NA4 (30,34,44,51) 86 1-8-4 3.7 108 
 
